Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Gross Profit: 2009-2024

Historic Gross Profit for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $1.4 million.

  • Northwest Biotherapeutics' Gross Profit fell 43.98% to $200,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $937,000, marking a year-over-year decrease of 41.29%. This contributed to the annual value of $1.4 million for FY2024, which is 28.47% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Gross Profit of $1.4 million as of FY2024, which was down 28.47% from $1.9 million recorded in FY2023.
  • Over the past 5 years, Northwest Biotherapeutics' Gross Profit peaked at $1.9 million during FY2023, and registered a low of $1.0 million during FY2021.
  • Its 3-year average for Gross Profit is $1.7 million, with a median of $1.7 million in 2022.
  • Its Gross Profit has fluctuated over the past 5 years, first tumbled by 46.43% in 2020, then surged by 67.46% in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Gross Profit (Yearly) stood at $1.3 million in 2020, then declined by 22.15% to $1.0 million in 2021, then skyrocketed by 67.46% to $1.7 million in 2022, then rose by 14.80% to $1.9 million in 2023, then decreased by 28.47% to $1.4 million in 2024.